Pharmacokinetic enhancers in HIV therapeutics (Q38244014)

31 August 2017

Pharmacokinetic enhancers in HIV therapeutics (English)

1 reference

31 August 2017

0 references

1 reference

Kajal B Larson

1

1 reference

31 August 2017

Kun Wang

2

1 reference

31 August 2017

Cecile Delille

3

1 reference

31 August 2017

Igho Otofokun

4

1 reference

31 August 2017

Edward P Acosta

5

1 reference

31 August 2017

1 October 2014

1 reference

Clinical Pharmacokinetics

31 August 2017

1 reference

31 August 2017

53

1 reference

31 August 2017

865-872

1 reference

31 August 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1007/s40262-014-0167-9

31 August 2017

0 references

cites work

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Protease inhibitor-associated diabetes mellitus: a potential cause of morbidity and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Cobicistat: a new boost for the treatment of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

How an inhibitor of the HIV-I protease modulates proteasome activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Treatment outcomes amongst previously antiretroviral-naïve HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 r

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resul

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

TMC310911, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, Shows In Vitro an Improved Resistance Profile and Higher Genetic Barrier to Resistance Compared with Current Protease Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Safety and pharmacokinetics of the HIV-1 protease inhibitor TMC310911 coadministered with ritonavir in healthy participants: results from 2 phase 1 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

21 January 2018

12 December 2020

The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Induction effects of ritonavir: implications for drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0167-9

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

21 January 2018

1 reference

12 December 2020

Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.

1 reference

12 December 2020

Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients

1 reference

12 December 2020

Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism

1 reference

12 December 2020

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

1 reference

12 December 2020

ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease

1 reference

12 December 2020

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

1 reference

12 December 2020

Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.

1 reference

12 December 2020

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects

1 reference

12 December 2020

Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A

1 reference

12 December 2020

Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection.

1 reference

12 December 2020

10.1007/S40262-014-0167-9

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

0 references

1 reference